


PHARMACEUTICAL 2022



UroGen Pharma Ltd. Rank 387 of 475









UroGen Pharma Ltd. Rank 387 of 475

The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 69% points. The greatest weakness of UroGen Pharma Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 196% points.

The company's Economic Capital Ratio, given in the ranking table, is -382%, being 105% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	114,390
Cost of Goods Sold	5,157
Intangible Assets	0
Liabilities, Current	22,380
Liabilities, Non-Current	398
Other Assets	3,389
Other Compr. Net Income	-296
Other Expenses	18,740
Other Liabilities	88,555
Other Net Income	212
Property and Equipment	1,967
Research and Development	47,642
Revenues	48,042
Selling, General and Administrative Expense	87,535

Output Variable	Value in 1000 USD
Assets	119,746
Liabilities	111,333
Expenses	159,074
Stockholders Equity	8,413
Net Income	-110,820
Comprehensive Net Income	-110,968
Economic Capital Ratio	-382%

